This post will attempt to refute the unwarranted downgrade by Friedman, Billings Ramsey & Co. analyst Jim Reddoch, following the late-stage clinical trial results of Erbitux that were released on June 6, 2006.
Both Fridman, Billings Ramsey & Co and Citigroup cited the following concerns as...